IGI Laboratories, Inc., a New Jersey-based specialty generic pharmaceutical company, has entered into an agreement to acquire the assets of Alveda Pharmaceuticals, Inc. for $47 million CAD in cash.

Alveda Pharmaceuticals, Inc. is a Canadian generic pharmaceutical company focused on providing the Canadian healthcare system with essential injectable pharmaceutical products. Products are supplied through Alveda's long-term partnerships with reputable European contract manufacturing organizations. Alveda currently markets 17 molecules in the Canadian market through its 36 injectables and is the market leader in Canada for most of the products in the Alveda catalogue.

Jason Grenfell-Gardner, president and CEO of IGI, commented, "This transaction should deliver contribution to our fourth quarter of 2015 financial results via a profitable commercial platform and growing pipeline of hospital-administered injectable products in Canada. The Alveda management team has a strong track record with the Canadian institutional supply chain including group purchasing organizations, wholesalers, and individual hospitals.The Alveda in-house regulatory team has been quite productive, and, as a result, Alveda currently has a pipeline of 8 products, 4 of which are pending approval by Health Canada.''

''This acquisition allows us to extend our TICO strategy into Canada,'' continued Grenfell-Gardner. ''This sector of the Canadian market typically offers timely generic approvals from Health Canada, which, together with the Alveda team, should accelerate the growth of IGI in Canada."

Albert Beraldo, president and CEO of Alveda Pharmaceuticals Inc., stated, "IGI's acquisition of the Alveda product line will further accelerate development of our proven business model. IGI provides a fantastic opportunity for the Alveda business to further expand product and service offerings for the benefit of patients throughout Canada."

The transaction is expected to close before the end of November, 2015, subject to customary closing conditions.

Alveda has projected net sales of approximately $16.0M CAD for their fiscal year ended September 30, 2015.

Alveda's marketed injectable products include atropine sulphate, acetylcysteine, dimenhydrinate, ergonovine maleate, furosemide, irinotecan, lidocaine, lidocaine with epinephrine, piperacillin tazobactam, methylene blue, naloxone, succinylcholine chloride, sodium chloride, sterile water, epinephrine.